The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.

In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thi-azol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

This invention relates to a formulation comprising a proteinaceous microgel and one or more biopolymeric nanofibrils. The invention also relates to methods for preparing such formulations. The invention also contemplates the uses of the formulations.

Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.

Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.

Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.

##STR00001##

Provided herein are methods and compositions for the delivery of at least two active, therapeutic, or pharmaceutical agents in an oil-in-water emulsion, wherein at least one agent is delivered in the hydrophobic phase of the emulsion and at least one agent is delivered in the aqueous phase of the emulsion.

Provided herein are methods and compositions for the delivery of at least two active, therapeutic, or pharmaceutical agents in an oil-in-water emulsion, wherein at least one agent is delivered in the hydrophobic phase of the emulsion and at least one agent is delivered in the aqueous phase of the emulsion.

The invention discloses a cannabinoid nano-micelle preparation and a preparation method thereof. The cannabinoid nano-micelle preparation includes cannabinoid and an amphiphilic polymer, wherein the content of the cannabinoid is 1-40% by weight, the content of the amphiphilic polymer is 1-99%, and the preparation method includes the following steps: (1) preparing a cannabinoid nano-micelle solution from cannabinoid and an amphiphilic polymer; (2) drying the micellar solution obtained in the step (1) to obtain cannabinoid nano-micelle powder; and (3) preparing the cannabinoid nano-micelle powder obtained in the step (2) into the cannabinoid nano-micelle preparation. The cannabinoid nano-micelle preparation is high in effective component wrapping rate and transfer rate, high in drug loading capacity and high in stability, and a novel normal-temperature self-assembly technology is adopted, so that an active component cannabinoid is prevented from being degraded and discolored at high temperature; the bioavailability of the active ingredient is high, and a single dose can be reduced. Especially, a dry powder inhalant is high in in-vitro deposition rate and quick in inhalation effect, and can provide continuous and stable blood concentration.